A novel thiobarbituric-like compound MDG548, which acts as a functional PPARγ agonist, was tested in vitro and in vivo models of PD, MDG548 protected against H2O2 and MPP+ neurotoxicity in PC12 cells and in the mice treated with MPTP, the MDG548 reduced reactive microglia and iNOS induction in the substantia nigra [91]. This evidence concerns the gene PPARG and Parkinson disease.